3 Top Biotech Stocks for New Year 2023

January 11, 2023 www.tradewins.com Other Exciting News Calendar Spreads: Seeking Profit From Theta Time Decay Tuesday, January 17th at 3:30pm CT In this webinar guest speaker, author, educator and trader, Rob Roy will do a deep dive into Calendar Spreads including how to set them up and how you can use them to seek profits in your trading. Be sure to Register Here Now to increase your options trading knowledge and get your questions answered live! All attendees will receive a free gift courtesy of Rob and the recorded replay. Don't miss out on this FREE educational opportunity on options trading! Register Here Today! Recent Articles 3 Top Biotech Stocks for New Year 2023 by Ian Cooper Using "The Free Trade" To Construct a Large Position by David L. Caplan Keith’s Outlier Watch List by Keith Harwood TradeWins Author Team     Tomorrow, you could begin doubling your account every single month starting with one letter. The letter will come from a 20-year trading professional named Ian Cooper. He says, “In 2022, following my trades you would be doubling even tripling your account some months. Let me show you how.” He will show you exactly what to do... and he’ll give you the blueprint for just $1. Get Daily Trade Alert Now About TradeWins Inside Trading Newsletter Webinars Videos Trading Strategy Options Futures Forex Day Trading Subscription Services E-Books Customer Satisfaction Survey 2020 3 Top Biotech Stocks for New Year 2023 by Ian Cooper Investors may want to keep an eye on the biotech boom. For one, the sector is still one of the safest, most recession-proof investments around. Two, an aging population is demanding better treatment in an effort to live longer lives. Three, there’s incredible new innovation in gene therapies, immune-oncology, precision medicine, machine-learning drug discovery, and treatments for unmet medical needs. All of which is attracting millions of investors into the red-hot biotech space. With that, here are five ways to invest in the biotech story. SPDR S&P Biotech ETF (XBI) One of the best ways to diversify at less cost is with a biotech ETF, such as the SPDR S&P Biotech ETF (XBI). With an expense ratio of 0.35%, the ETF offers exposure to the S&P Biotechnology Select Industry Index. Some of its top holdings include Biogen, Veracyte, Moderna, Gilead Sciences, Amgen, and VIr Biotechnology to name a few. Other top biotech ETFs include the IBB ETF, which holds dozens of stocks, including Amgen, Vertex, Gilead Sciences, Illumina, Regeneron, and Biogen to name a few. The IBB, which has an expense ratio of 0.44%, last trade around $133. Or, look at the Ultra NASDAQ Biotechnology ETF (BIB). Read More   Using "The Free Trade" To Construct a Large Position by David L. Caplan The "free trade" combines the best principles of money management and taking advantage of "undervalued" and "overvalued" options. However, the most exciting aspect of the "free trade" is that it can allow you to build a large position in a trending market without risking your initial risk. To initiate the "free trade," first purchase the best-priced option. Then, when (and if) the price and volatility (premium) rise, sell a further out-of-the-money option at the same price. (Of course, if the market does not move in your favor, you cannot complete the "free trade.") Another benefit of the "free trade" is that after it is completed there is no margin, capital necessary, or potential loss (other than brokerage fees and costs). The "free trade" accomplishes several objectives: First, it keeps your account intact if the market turns around. Just as quickly as markets rise, they can also fall. The "free trade" position provides protection from loss in this situation (see chart). Read More Keith’s Outlier Watch List by Keith Harwood Keith’s Outlier Watch List is actually comprised of two separate lists…   Candidates for our Big League Options portfolio of stocks trending above other stocks in the NASDAQ 100… average open profit 128.5%. Candidates for our Home Run Swing Trader, including the trigger price for entry… average profit 239.45% in less than 30 days. Click Here to check out one of this week’s recommendations. Read More   www.tradewins.com                © Copyright 2023 TradeWins.com. All rights reserved. TradeWins Publishing, 22C New Leicester Hwy, #117, Asheville, NC 28806 Email: support@iss-trading.com   |   Phone: 888-233-1431   |   Fax: 888-258-4938   PLEASE READ: Auto-trading, or any broker or advisor-directed type of trading, is not supported or endorsed by TradeWins. For additional information on auto-trading, you may visit the SEC’s website: All About Auto-Trading, TradeWins does not recommend or refer subscribers to broker-dealers. You should perform your own due diligence with respect to satisfactory broker-dealers and whether to open a brokerage account. You should always consult with your own professional advisers regarding equities and options on equities trading. 1) The information provided by the newsletters, trading, training and educational products related to various markets (collectively referred to as the “Services”) is not customized or personalized to any particular risk profile or tolerance. Nor is the information published by TradeWins Publishing (“TradeWins”) a customized or personalized recommendation to buy, sell, hold, or invest in particular financial products. The Services are intended to supplement your own research and analysis. 2) TradeWins’ Services are not a solicitation or offer to buy or sell any financial products, and the Services are not intended to provide money management advice or services. 3) Past performance is not necessarily indicative of future results. Trading and investing involve substantial risk. Trading on margin carries a high level of risk, and may not be suitable for all investors. Other than the refund policy detailed elsewhere, TradeWins does not make any guarantee or other promise as to any results that may be obtained from using the Services. No person subscribing for the Services (“Subscriber”) should make any investment decision without first consulting his or her own personal financial adviser, broker or consultant. TradeWins disclaims any and all liability in the event anything contained in the Services proves to be inaccurate, incomplete or unreliable, or results in any investment or other loss by a Subscriber. 4) You should trade or invest only “risk capital” – money you can afford to lose. Trading stocks and stock options involves high risk and you can lose the entire principal amount invested or more. 5) All investments carry risk and all trading decisions made by a person remain the responsibility of that person. There is no guarantee that systems, indicators, or trading signals will result in profits or that they will not produce losses. Subscribers should fully understand all risks associated with any kind of trading or investing before engaging in such activities. 6) Some profit examples are based on hypothetical or simulated trading. This means the trades are not actual trades and instead are hypothetical trades based on real market prices at the time the recommendation is disseminated. No actual money is invested, nor are any trades executed. Hypothetical or simulated performance is not necessarily indicative of future results. Hypothetical performance results have many inherent limitations, some of which are described below. Also, the hypothetical results do not include the costs of subscriptions, commissions, or other fees. Because the trades underlying these examples have not actually been executed, the results may understate or overstate the impact of certain market factors, such as lack of liquidity. Simulated trading services in general are also designed with the benefit of hindsight, which may not be relevant to actual trading. In addition, hypothetical trading does not involve financial risk, and no hypothetical trading record can completely account for the impact of financial risk of actual trading. TradeWins makes no representations or warranties that any account will or is likely to achieve profits similar to those shown. 7) No representation is being made that you will achieve profits or the same results as any person providing testimonial. No representation is being made that any person providing a testimonial is likely to continue to experience profitable trading after the date on which the testimonial was provided, and in fact the person providing the testimonial may have experienced losses. 8) The author experiences are not typical. The author is an experienced investor and your results will vary depending on risk tolerance, amount of risk capital utilized, size of trading position and other factors. Certain Subscribers may modify the author methods, or modify or ignore the rules or risk parameters, and any such actions are taken entirely at the Subscriber’s own election and for the Subscriber’s own risk.

If you wish to stop receiving our emails or change your subscription options, please Manage Your Subscription
TradeWins Publishing, 528 North Country Rd., St. James, NY 11780

Share on Facebook

Share on Twitter

Share on Google+

Share on LinkedIn

Subscribe to receive free email updates: